What's new

COVID-19 vaccine: First 'milestone' vaccine offers 90% protection

Do you believe that the new Pfizer vaccine will be effective?


  • Total voters
    15
Why do this if the vaccine was set for great things? Surely he’s not hard up for cash on his salary.

<blockquote class="twitter-tweet"><p lang="en" dir="ltr">Pfizer CEO sold 60 PERCENT of his stock for $5.6M the DAY of the vaccine announcement <a href="https://t.co/JDAmlQMnOS">https://t.co/JDAmlQMnOS</a></p>— Daily Mail US (@DailyMail) <a href="https://twitter.com/DailyMail/status/1326545571780259840?ref_src=twsrc%5Etfw">November 11, 2020</a></blockquote> <script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

I doubt the govt would approve any vaccine unless it has passed stringent testing. Imagine the lawsuit potential if they pushed through mass vaccination and there were health issues down the line. Oh wait...they probably wouldn't be the govt by that time.
 
There is so much rubbish out there on the internet.
Conspiracies about this and that.

I would urge anyone with doubts to speak to a doctor or a friend or family in the field (science/medicine) who can put your minds at ease.

That's true but I wouldn't completely write it off. For any topic that can affect your health, finance or any aspect of your life, it is important check the website for its authoritativeness, expertise and trustworthiness.

This means you can trust sites like NHS, Patient.info, CDC, WebMD, Mayo Clinic etc as the content is written by medical professionals and they have a high degree of authority and expertise.

The information on these sites would obviously be more credible than some random guy posting on Reddit or some other non medical forums.
 
Covid-19: Normal life back next winter, says vaccine creator

The impact of a new Covid vaccine will kick in significantly over summer and life should be back to normal by next winter, one of its creators has said.

Prof Ugur Sahin, co-founder of BioNTech, said this winter would still be hard as the vaccine would not have a big impact on infection numbers.

Last week, BioNTech and co-developers Pfizer said preliminary analysis showed their vaccine could prevent more than 90% of people from getting Covid-19.

About 43,000 people took part in tests.

The UK is expected to get 10 million doses by the end of the year, with a further 30 million doses already ordered. The vaccine is given in two doses, three weeks apart.

Older residents and staff in care homes are likely to be prioritised, followed by health workers and the over-80s. People would then be ranked by age.

In an interview on BBC's Andrew Marr Show, Prof Sahin said he was confident the vaccine would reduce transmission between people as well as stop symptoms developing in someone who has had the vaccine.

It was possible, he said, the vaccine could halve transmission which would have a big impact.

"I'm very confident that transmission between people will be reduced by such a highly effective vaccine - maybe not 90% but maybe 50% - but we should not forget that even that could result in a dramatic reduction of the pandemic spread," he added.

After the announcement of the world's first effective vaccine came on Monday, Sir John Bell, regius professor of medicine at Oxford University, suggested life could be back to normal by spring.

"I am probably the first guy to say that, but I will say that with some confidence," he said.

However, Prof Sahin said it would take longer.

If everything continued to go well, he said, the vaccine would begin to be delivered at the "end of this year, beginning of next year".

The goal was to deliver more than 300 million doses worldwide by next April, he said, which "could allow us to only start to make an impact".

He said the bigger impact would happen later, adding: "Summer will help us because the infection rate will go down in the summer and what is absolutely essential is that we get a high vaccination rate until or before autumn/winter next year."

Prof Sahin said it was essential that all immunisation programmes were completed before next autumn.

Read more: https://www.bbc.com/news/health-54949799
 
U.S. Biotech firm Moderna says interim results show their potential vaccine is 94.5% effective at protecting people from covid-19
 
Moderna has gone out to say it doesn’t require such low temp storage as well? Wonder if thats the reason Pfizer ceo sold his stock?
 
Moderna has gone out to say it doesn’t require such low temp storage as well? Wonder if thats the reason Pfizer ceo sold his stock?

I don't get why people are so hung up on the Pfizer CEO selling his stock. He sold it to maximise his gains. This is probably the highest the Pfizer stock is going to be on account of it being the first vaccine over the line. He probably knows it won't be the best vaccine in the market. As more and more firms unveil their results and present more advanced vaccines due to taking longer with their development, it will put downward pressure on Pfizer's stock.

He timed the market to maximise his gains as any shrewd investor would do. As long as he sold the stock after the announcement was made and all known information was made public there is no market manipulation going on.
 
Last edited:
U.S. Biotech firm Moderna says interim results show their potential vaccine is 94.5% effective at protecting people from covid-19

Moderna: Covid vaccine shows nearly 95% protection

A new vaccine that protects against Covid-19 is nearly 95% effective, early data from US company Moderna shows.

The results come hot on the heels of similar results from Pfizer, and add to growing confidence that vaccines can help end the pandemic.

Both companies used a highly innovative and experimental approach to designing their vaccines.

Moderna says it is a "great day" and they plan to apply for approval to use the vaccine in the next few weeks.

However, this is still early data and key questions remain unanswered.

How good is it?

The trial involved 30,000 people in the US with half being given two doses of the vaccine, four weeks apart. The rest had dummy injections.

The analysis was based on the first 95 to develop Covid-19 symptoms.

Only five of the Covid cases were in people given the vaccine, 90 were in those given the dummy treatment. The company says the vaccine is protecting 94.5% of people.

The data also shows there were 11 cases of severe Covid in the trial, but none happened in people who were immunised.

"The overall effectiveness has been remarkable... it's a great day," Tal Zaks, the chief medical officer at Moderna, told BBC News.

Dr Stephen Hoge, the company's president, said he "grinned ear to ear for a minute" when the results came in.

He told BBC News: "I don't think any of us really hoped that the vaccine would be 94% effective at preventing Covid-19 disease, that was really a stunning realisation."

Read more: https://www.bbc.com/news/health-54902908
 
I don't get why people are so hung up on the Pfizer CEO selling his stock. He sold it to maximise his gains. This is probably the highest the Pfizer stock is going to be on account of it being the first vaccine over the line. He probably knows it won't be the best vaccine in the market. As more and more firms unveil their results and present more advanced vaccines due to taking longer with their development, it will put downward pressure on Pfizer's stock.

He timed the market to maximise his gains as any shrewd investor would do. As long as he sold the stock after the announcement was made and all known information was made public there is no market manipulation going on.

I have no issues ,just assuming the reason.. I’m all for capitalism.
 
<blockquote class="twitter-tweet"><p lang="en" dir="ltr">Another Vaccine just announced. This time by Moderna, 95% effective. For those great “historians”, please remember that these great discoveries, which will end the China Plague, all took place on my watch!</p>— Donald J. Trump (@realDonaldTrump) <a href="https://twitter.com/realDonaldTrump/status/1328341927641681922?ref_src=twsrc%5Etfw">November 16, 2020</a></blockquote> <script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
 
Moderna has gone out to say it doesn’t require such low temp storage as well? Wonder if thats the reason Pfizer ceo sold his stock?

I don't get why people are so hung up on the Pfizer CEO selling his stock. He sold it to maximise his gains. This is probably the highest the Pfizer stock is going to be on account of it being the first vaccine over the line. He probably knows it won't be the best vaccine in the market. As more and more firms unveil their results and present more advanced vaccines due to taking longer with their development, it will put downward pressure on Pfizer's stock.

He timed the market to maximise his gains as any shrewd investor would do. As long as he sold the stock after the announcement was made and all known information was made public there is no market manipulation going on.

Insider stock sales such as that of CEO's CFOs etc. are usually undertaken months before the actual date. They have to sign several disclosure agreements and the reason for this is so that companies don't take advantage of news based stock surge.

So this whole thing about Pfizer CEO selling stock right after is not correct. He actually sold it 3 months ago, and the process went through just now.
 
Insider stock sales such as that of CEO's CFOs etc. are usually undertaken months before the actual date. They have to sign several disclosure agreements and the reason for this is so that companies don't take advantage of news based stock surge.

So this whole thing about Pfizer CEO selling stock right after is not correct. He actually sold it 3 months ago, and the process went through just now.

Thanks makes sense, good business decision..
 
Moderna's vaccine is better, it's 95% effective and doesn't require extremely low temperature storage and they're saying they'll have 60 million ready by next month. Apparently the tech they got is way ahead of Pfizer as they've been working with mRNA for the past decade.
 
Govt of Pakistan in talks with two companies for Coronavirus vaccine - In the first phase, 10 million Pakistanis will get the vaccine. Frontline workers and people over 65 years old will be given priority.
 
Last edited:
WHO chief warns that vaccine alone wouldn't end COVID pandemic

(MENAFN - NewsIn.Asia) November 17 (CBS News) - The head of the World Health Organization said Monday that a vaccine would not by itself stop the coronavirus pandemic.

The pandemic is raging months after it broke out, with infections soaring past 54 million and claiming more than 1.3 million lives.

"A vaccine will complement the other tools we have, not replace them," director-general Tedros Adhanom Ghebreyesus said. "A vaccine on its own will not end the pandemic."

The WHO's figures for Saturday showed that 660,905 coronavirus cases were reported to the United Nations health agency, setting a new high water mark.

That number, and the 645,410 registered on Friday, surpassed the previous daily record high of 614,013 recorded on November 7.

Tedros said supplies of the vaccine would initially be restricted, with "health workers, older people and other at-risk populations being prioritized. That will hopefully reduce the number of deaths and enable the health systems to cope."

But he warned, "That will still leave the virus with a lot of room to move. Surveillance will need to continue, people will still need to be tested, isolated and cared for, contacts will still need to be traced … and individuals will still need to be cared for."

Source: https://menafn.com/1101137605/WHO-chief-warns-that-vaccine-alone-wouldnt-end-COVID-pandemic.
 
Pharmaceutical company Pfizer says primary analysis suggests its potential vaccine is "95% effective against COVID-19 beginning 28 days after the first dose" - a rise on its previous suggestion that it was 90% effective
 
Covid vaccine: Pfizer says it's '94% effective in over 65s'

The coronavirus vaccine developed by Pfizer and BioNTech appears to protect 94% of adults over 65 years old.

More data released from their ongoing phase three trial suggests it works equally well in people of all ages, races and ethnicities.

The companies say they will now apply for authorisation for emergency use of the jab in the US.

The findings are based on two doses given to more than 41,000 people around the world.

Last week, Pfizer and BioNTech published preliminary data showing the vaccine offered 90% protection against Covid-19 and there were no safety concerns.

This was followed by impressive data on another vaccine, made by US company Moderna, suggesting nearly 95% protection.

Today's data from Pfizer and BioNTech suggests the vaccine is 95% effective based on 170 cases of Covid-19 developing in volunteers - just eight were in the group given the vaccine, suggesting it offers good protection.

The rest of the cases were in the placebo group given a dummy jab.

The companies say there have been no serious safety concerns, but they did notice headaches and fatigue in around 2% of volunteers given the vaccine.

In the trial, 42% of all participants are from diverse ethnic backgrounds and 41% are aged between 56 and 85 years old.

The trial is still continuing, and will collect data on the safety and efficacy of the vaccine for another two years.

The vaccine is being tested on people at 150 sites in the US, Germany, Turkey, South Africa, Brazil and Argentina.

The companies expect to produce up to 50 million doses of the vaccine this year and up to 1.3 billion doses by the end of 2021.

The UK has pre-ordered 40 million doses of this vaccine and should get 10 million by the end of the year.

https://www.bbc.com/news/health-54986208
 
The COVID-19 vaccine developed by Oxford University produces a strong immune response in older adults, data from early trials has shown.

The phase one and phase two results suggest that one of the groups most at risk of death or serious illness from COVID-19 may be able to build immunity, according to data published in The Lancet medical journal.
 
AstraZeneca COVID-19 vaccine shows promise in elderly, trial results by Christmas

LONDON (Reuters) - AstraZeneca and Oxford University’s potential COVID-19 vaccine produced a strong immune response in older adults, data published on Thursday showed, with researchers expecting to release late-stage trial results by Christmas.

The data, reported in part last month but published in full in The Lancet medical journal on Thursday, suggest that those aged over 70, who are at higher risk of serious illness and death from COVID-19, could build robust immunity.

“The robust antibody and T-cell responses seen in older people in our study are encouraging,” said Maheshi Ramasamy, a consultant and co-lead investigator at the Oxford Vaccine Group.

“We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure.”

Late-stage, or Phase III, trials are ongoing to confirm the findings, researchers said, and to test whether the vaccine protects against infection with SARS-CoV-2 in a broad range of people, including people with underlying health conditions.

Results of those trials should definitely be known by Christmas, the Oxford Vaccine Group’s director, Andrew Pollard, said, adding it was too early to know whether and how well the vaccine works in preventing COVID-19 disease.

“We’re still waiting to get to the point where we can do the analysis to just work out how well the vaccine can protect people, and we’re getting ever closer to that,” he told journalists.

“We are optimistic that we’ll be able to do that before Christmas, and obviously we’ll share that with you as soon as we can at that point.”

The Oxford-AstraZeneca COVID-19 vaccine candidate, called AZD1222 or ChAdOx1 nCoV-19, had been among the front-runners in global efforts to develop shots to protect against infection with the novel coronavirus, or SARS-CoV-2.

But rival drugmakers Pfizer Inc PFE.N, BioNTech 22UAy.F and Moderna Inc MRNA.O have in the past 10 days edged ahead, releasing data from late-stage COVID-19 vaccine trials that shows more than 90% efficacy.

“We’re not in a rush. We and it’s not a competition with the other developers,” Oxford’s Pollard said, adding that AstraZeneca would release headline efficacy data before it was published in an academic journal.

Oxford University has set a target of 53 infections to start the interim analysis of its late-stage trial results, though “lots of cases” in its trial arms in Britain, South Africa and Brazil mean the exact number of infections reported could differ.

Unlike the Pfizer-BioNTech and Moderna shots, both of which use new technology known as messenger RNA (mRNA), AstraZeneca’s is a viral vector vaccine made from a weakened version of a common cold virus found in chimpanzees.

The Phase II trial reported in The Lancet involved a total of 560 healthy volunteers, with 160 aged 18-55, 160 aged 56-69, and 240 aged 70 or over.

Volunteers got two doses of the vaccine or a placebo, and no serious side effects related to the AZD1222 vaccine were reported, the researchers said.

AstraZeneca AZN.L has signed several supply and manufacturing deals with companies and governments around the world.

https://www.reuters.com/article/us-...erly-trial-results-by-christmas-idUSKBN27Z0PF
 
Pfizer boss: 'We are ready to send out vaccine within hours'

The boss of Pfizer has told Sky News that his company is poised to send out doses of its COVID-19 vaccine "within hours" of it receiving official approval.

Chief executive Albert Bourla said that his company would be applying for permission from regulatory authorities across the world "very, very soon - within a couple of days" and was then ready to start shipping the first of 20 million vaccine doses that have already been made.

He told Europe correspondent Adam Parsons that doses would be sent out to countries as soon as their health authorities gave permission, raising the possibility of a "race to regulate", but said the world would have to be "patient" because demand would outstrip supply.

"The light is real - there is light at the end of the tunnel," he said. "I believe that the second half of 2021 will be a very different experience for many of us."

Mr Bourla spoke to Sky News exclusively, shortly after his company had concluded its phase 3 study into its COVID-19 vaccine, created in partnership with the German firm BioNTech.
 
Really need Astrazeneca to work for India’s sake, institute is ready to roll that out in big numbers!
 
The Oxford-AstraZeneca vaccine for the coronavirus disease could become available for the general public by April-May next year and is likely to cost around ₹500-600 for a dose, Serum Institute of India CEO Adar Poonawalla
 
Pfizer to apply for authorisation in US

Pfizer and its partner BioNTech have said they will apply for emergency authorisation in the US for their Covid-19 vaccine on Friday.

It will be the job of the US Food and Drug Administration (FDA) to decide if the vaccine is safe to roll out.

It is not clear how long the FDA will take to study the data. However, the US government expects to approve the vaccine in the first half of December.

Data from an advanced trial showed the vaccine protects 94% of adults over 65.

The trial involved 41,000 people worldwide. Half were given the vaccine, and half a placebo.

The UK has pre-ordered 40 million doses and should get 10 million by the end of the year.

Last week, Pfizer and BioNTech published preliminary data suggesting the vaccine offered 90% protection against Covid-19 and said there were no safety concerns. Subsequent data released on Wednesday suggested 95% effectiveness.

This was followed by data on a vaccine made by US company Moderna suggesting nearly 95% protection and similarly promising results from trials of another developed in Russia, called Sputnik.Prof Stephen Evans, professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine (LSHTM), said both the FDA and the European Medicines Agency (EMA) would need to approve the Pfizer data.

"We can expect both agencies to conduct a very careful evaluation and we can rely on their conclusions," he said.

But BBC health correspondent Naomi Grimley says this vaccine is still a long way off widespread use as regulators need to be absolutely sure that it's safe - not least because Moderna and Pfizer both use an experimental technology that has never been approved before.

https://www.bbc.com/news/health-55016023
 
The World Health Organization (WHO) is advising against the use of a drug Donald Trump took while suffering with coronavirus.

In May, Health Secretary Matt Hancock called the approval of the medicine for NHS patients the "biggest step forward in the treatment of coronavirus since the crisis began".

Remdesivir - also known as Veklury - is an antiviral therapeutic made by Gilead, and was originally intended to be used as an Ebola treatment.

However, new guidelines published by the WHO in The British Medical Journal found "a lack of evidence that remdesivir improved outcomes that matter to patients such as reduced mortality, need for mechanical ventilation, time to clinical improvement, and others".
 
Covid: Jab for people who cannot be vaccinated trialled

A possible alternative to a vaccine, for people without functioning immune systems, is entering its final stage of trials.

The injection was developed using antibodies - made by the immune system to fight infection - produced by a single Covid patient in the US.

It is hoped it could provide at least six months' protection for patients who cannot receive vaccines.

Trials involving 1,000 UK participants begin in Manchester on Saturday.

A further 4,000 people are involved in the trial globally, which is being organised by pharmaceutical giant AstraZeneca.

Participants will be given either an injection containing two different Covid-19 antibodies, which have been specially engineered to last longer in the body - or a placebo.

In recent weeks there have been promising developments in the creation of a Covid-19 vaccine, which works by priming the immune system to fight off the infection.

But the UK's Vaccine Taskforce chair, Kate Bingham, estimates hundreds of thousands people might not benefit from a vaccine because they do not have a working immune system.

This might be due to an immune deficiency, or because they are taking immune-suppressing drugs, for diseases such as cancer.

"It's crucial that we leave no one behind as we move closer to finding both a vaccine and developing more treatments for Covid-19," she said.

"We particularly need to ensure those who cannot be given a vaccine, such as people who are immuno-compromised, have alternatives available that will help protect them."

AstraZeneca, which is developing the antibody injection, hopes it will offer 6-12 months' protection.

Study lead Prof Andrew Ustianowski said, while vaccines work "by inducing a person's immune system to produce antibodies that inhibit or 'neutralise' the virus", his team are investigating whether similar protection could be given to the immuno-compromised, by injecting antibodies which have been shown to neutralise the virus directly into the muscle.

This bypasses the immune system for those people who "don't respond well to vaccines, or cannot be given them".

However, the therapy is significantly more expensive than vaccination and difficult to produce at scale, so it is unlikely to be used on the wider population.

Nine UK trial sites have been identified so far, in Manchester, London, Plymouth, Southampton, West Yorkshire, Enfield, Rochdale and Preston. The first results are expected next spring.

The trial will assess whether the therapy is effective and whether it is safe.

https://www.bbc.com/news/health-55022288
 
Saudi King Salman: G20 leaders must work towards equitable access to COVID-19 vaccines

DUBAI (Reuters) - Saudi Arabia’s King Salman said in his opening remarks to G20 leaders on Saturday that they must work towards affordable and equitable access to vaccines and other tools to combat the COVID-19 pandemic.

“Although we are optimistic about the progress made in developing vaccines, therapeutics and diagnostics tools for COVID-19, we must work to create the conditions for affordable and equitable access to these tools for all peoples,” he said, opening the meeting of the leaders of the 20 biggest world economies.

https://www.reuters.com/article/us-...ccess-to-covid-19-vaccines-idUSKBN2810HX?il=0
 
Moderna to charge $25-$37 for COVID-19 vaccine: CEO tells paper

Moderna will charge governments between $25 and $37 per dose of its COVID-19 vaccine candidate, depending on the amount ordered, Chief Executive Stephane Bancel told German weekly Welt am Sonntag (WamS).

“Our vaccine therefore costs about the same as a flu shot, which is between $10 and $50,” he was quoted as saying.

On Monday, an EU official involved in the talks said the European Commission wanted to reach a deal with Moderna for the supply of millions of doses of its vaccine candidate for a price below $25 per dose.

“Nothing is signed yet, but we’re close to a deal with the EU Commission. We want to deliver to Europe and are in constructive talks,” Bancel told WamS, adding it was just a “matter of days” until a contract would be ready.

Moderna has said its experimental vaccine is 94.5% effective in preventing COVID-19, based on interim data from a late-stage clinical trial, becoming the second developer to report results that far exceeded expectations after Pfizer and its partner BioNTech.

The EU has been in talks with Moderna for its experimental COVID-19 vaccine at least since July.

https://www.brecorder.com/news/40034447/moderna-to-charge-25-37-for-covid-19-vaccine-ceo-tells-paper
 
Moderna to charge $25-$37 for COVID-19 vaccine: CEO tells paper

Moderna will charge governments between $25 and $37 per dose of its COVID-19 vaccine candidate, depending on the amount ordered, Chief Executive Stephane Bancel told German weekly Welt am Sonntag (WamS).

“Our vaccine therefore costs about the same as a flu shot, which is between $10 and $50,” he was quoted as saying.

On Monday, an EU official involved in the talks said the European Commission wanted to reach a deal with Moderna for the supply of millions of doses of its vaccine candidate for a price below $25 per dose.

“Nothing is signed yet, but we’re close to a deal with the EU Commission. We want to deliver to Europe and are in constructive talks,” Bancel told WamS, adding it was just a “matter of days” until a contract would be ready.

Moderna has said its experimental vaccine is 94.5% effective in preventing COVID-19, based on interim data from a late-stage clinical trial, becoming the second developer to report results that far exceeded expectations after Pfizer and its partner BioNTech.

The EU has been in talks with Moderna for its experimental COVID-19 vaccine at least since July.

https://www.brecorder.com/news/40034447/moderna-to-charge-25-37-for-covid-19-vaccine-ceo-tells-paper

For western world it’s quite cheaper( cheaper than regular flu shots). However, for sub-continent and African nations, it would be challenging to afford it.

If two shots are required and each of them cost somewhere around $25-37 US then I’m guessing it will cost roughly around INR 10,000 for each individual. I just hope Serum institute in Pune mass produce COVID vaccine and sell it for much affordable prices.
Lot of third world country will rely on cheaper vaccine produced in India.
 
Covid-19 pandemic: Merkel 'worried' about vaccines for poor countries

Germany's chancellor has raised concerns about the world's poorest securing access to Covid-19 vaccines.

Angela Merkel was speaking at a G20 summit which saw leaders promise a fair distribution of jabs.

But Mrs Merkel warned progress was slow, saying she would raise the matter with global vaccine alliance GAVI.

"We will now speak with GAVI about when these negotiations will begin because I am somewhat worried that nothing has been done on that yet," she said.

Her comments come as the US announced that some Americans could be vaccinated as early as 11 December.

The G20 summit of the world's leading economic powers was hosted by Saudi Arabia. Due to the pandemic meetings were held virtually.

During the conference, the world's richest nations promised to support poor countries whose economies have been badly damaged by the crisis, but gave few details about what spending would entail.

The virus has infected nearly 60 million people around the world since emerging in China last December, and killed almost 1.4 million.

G20 nations also pledged to address the immediate financing required to support the production and fair distribution of Covid-19 vaccines, as well as treatments for the virus, and tests.

"We will spare no effort to ensure their affordable and equitable access for all people," the group said in their closing communique.

At a news conference, Saudi Finance Minister Mohammed al-Jadaan emphasised that there was consensus among G20 nations that "if we leave any country behind, we will be behind".

Rich countries including the UK have already bought up huge numbers of vaccine doses from pharmaceutical firms.

French President Emmanuel Macron called on G20 leaders to "go further and faster" in supporting poorer nations by donating doses, forging industrial partnerships and even sharing intellectual property.

But the European Commission President Ursula von der Leyen said "more funding is needed," to plug a $4.5bn (£3.3bn) gap in the so-called ACT-Accelerator, a mechanism led by the World Health Organization that aims to ensure access to tests, treatments and vaccines for all.

Source: https://www.bbc.com/news/business-55037760.
 
The coronavirus vaccine developed by the University of Oxford stops 70% of people developing Covid symptoms, a large-scale trial shows.

It will be seen as a triumph, but it comes off the back of Pfizer and Moderna showing 95% protection.

However, the Oxford jab is far cheaper, and is easier to store and get to every corner of the world than the other two.

So it will play a significant role in tackling the pandemic, if it is approved by regulators.

There is also intriguing data that suggests perfecting the dose could increase protection up to 90%.

The UK government has pre-ordered 100 million doses of the Oxford vaccine, enough to immunise 50 million people.

Prime Minister Boris Johnson said: "Incredibly exciting news the Oxford vaccine has proved so effective in trials.

"There are still further safety checks ahead, but these are fantastic results."

The vaccine has been developed in around 10 months, a process that normally takes a decade.

"The announcement today takes us another step closer to the time when we can use vaccines to bring an end to the devastation caused by [the virus]," said the vaccine's architect Prof Sarah Gilbert.
 
70% is still really good as it effectively provides herd immunity, and the fact that it's far cheaper is significant.
 
70% is still really good as it effectively provides herd immunity, and the fact that it's far cheaper is significant.

Yeah, it's excellent. But there are a few things that make it potentially even better.

1- The mild-full dose regimen points to a 90 percent efficacy. They need to followup on that but if it holds, this will put the vaccine in the same ballpark as the two mRNA ones.

2- This will be much more cheaper. It's also way more easy to transport and deliver as it can be stored at 2-10 degree centigrade for up to 30 days. That is big plus for Africa and countries like Pakistan and India.

3- They will have about 3 billion doses by the end of 2021 as of now. I am sure this will increase after today's results. That is more than the combined number for Pfizer and Moderna.

4- The primary endpoint was prevention of severe covid. They passed that with flying colors. Not one severe or even moderate case in the vaccine arm. That is very good news. If the vaccine prevents severe/moderate covid in all cases, it is going to effectively end the pandemic. The 2nd/3rd generation of vaccines can then come and get rid of the virus.
 
Oxford vaccine success caveat

Away from England's new tiers, it has emerged that the dose of AstraZeneca and Oxford University's vaccine that was shown to be 90% effective was only tested in people aged 55 and under.

That's the claim made by Moncef Slaoui, the scientific head of the US's Operation Warp Speed, which is the programme to supply America with vaccines.

He told US reporters that the half-dose regime, which was discovered by accident, was only given to younger age groups.

Scientists across the globe are hoping to find vaccines that work in older people, who are most at risk from COVID-19.

Oxford's overall efficacy from two different dosing regimes in a phase three trial was announced last week at a combined figure of 70%.

A half dose followed by a full dose was found to be 90% effective according to a subset of data, but efficacy was 62% for people given two full doses.
 
Oxford Covid vaccine: Regulator asked to assess jab

The government has asked the regulator to assess the Oxford/AstraZeneca coronavirus vaccine, bringing the UK a step closer to a possible rollout.

The referral to the Medicines and Healthcare products Regulatory Agency (MHRA) marked "a significant first step" in getting the vaccine "approved for deployment", the government said.

It follows news that the jab was "highly effective" in advanced trials.

The UK government has pre-ordered 100m doses of the Oxford vaccine.

The government's latest request to the MHRA comes a week after the regulator was asked to assess the Pfizer/BioNTech vaccine.

Health Secretary Matt Hancock said the government was working "tirelessly" to be in the "best possible position to deploy a vaccine" as soon as one was approved by the MHRA.

"We have formally asked the regulator to assess the Oxford/AstraZeneca vaccine, to understand the data and determine whether it meets rigorous safety standards," he added.

The Department of Health and Social Care said the UK would be one of the first countries in the world to receive the vaccine, if it was authorised, with AstraZeneca set to have as many as 4 million doses ready for the UK by the end of the year and 40 million by the end of March 2021.

The government has also ordered 40 million doses of the Pfizer/BioNTech vaccine - which preliminary results showed stopped more than 90% of people developing Covid-19 symptoms.

If approved, a vaccine could be rolled out from December, Mr Hancock has said.

On Thursday, AstraZeneca said it was amending its study in the US following the accidental discovery that the vaccine appeared to perform best when a half dose was given followed by a full one, rather than two full doses.

It came after multiple news outlets in the UK and US reported that there were questions over the data on how effective the Oxford jab was.

Interim data from the trial showed three efficacy levels - an overall efficacy of 70%, a lower one of 62% and a high of 90%.

The company added that it was looking to get further confidence in the 90% efficacy found among volunteers who received the lower initial dose. It said it already had enough data from the trials to submit the vaccine for regulatory approval and would be doing this soon.

https://www.bbc.com/news/uk-55096434
 
Here in Canada lot of folks are opposed to taking vaccine, mostly due to fear of having severe side-effects. It seems govt is pushing general public to blindly trust these ‘so called test results’ and take the vaccine. I personally will wait many weeks if not months to see how it pans out.
 
Reading in the paper today that Americans are particularly hostile about the Oxford formula being developed in Britain. Claims that AstraZeneca were not forthcoming about their test results and published data selectively to reach a 90% success rate.

Now questions are being asked if a potentially multi-billion pound industry is being fought over by resorting to dirty tricks.
 
Here in Canada lot of folks are opposed to taking vaccine, mostly due to fear of having severe side-effects. It seems govt is pushing general public to blindly trust these ‘so called test results’ and take the vaccine. I personally will wait many weeks if not months to see how it pans out.

The side effects are because of the virus protein. Its very similar in other vaccines like tetanus, etc which we take regularly. I am baffled that people think side effects from a dead virus protein is worrying but the actual disease which gives much more side effect is ok?
 
Federal Minister for Planning and Development Asad Umar said on Monday that the National Command and Operations Centre (NCOC) has finalised recommendations for the procurement of coronavirus vaccines.

"NCOC today finalized its recommendations for procurement of COVID vaccine," tweeted Umar, who also chairs the national body. "These will be presented to the cabinet tomorrow for approval."

The minister said the recommendations were developed by a task force of experts headed by Special Assistant to PM on Health Dr Faisal Sultan.
 
The side effects are because of the virus protein. Its very similar in other vaccines like tetanus, etc which we take regularly. I am baffled that people think side effects from a dead virus protein is worrying but the actual disease which gives much more side effect is ok?

Quite frankly you can’t blame the masses. Firstly, most of them don’t even know the basics of science, and secondly, speed at which some many pharmaceutical companies are launching vaccine with 90%+ success rate, it kind makes it business stunt rather than finding a cure. This whole COVID saga have made people very skeptical of governments and to trust them with something(vaccine) to inject in our bodies is not sitting well. It all comes down to trust issues. Personally, I will not trust our government for anything, they are scumbags and Chinese slaves. I will rather continue to SOPs and wear mask than get in line for vaccine(of course it will change over the time depending on how vaccine is performing among those who took it). But for now, I’m not in any rush whatsoever. I just don’t trust our government
 
Quite frankly you can’t blame the masses. Firstly, most of them don’t even know the basics of science, and secondly, speed at which some many pharmaceutical companies are launching vaccine with 90%+ success rate, it kind makes it business stunt rather than finding a cure. This whole COVID saga have made people very skeptical of governments and to trust them with something(vaccine) to inject in our bodies is not sitting well. It all comes down to trust issues. Personally, I will not trust our government for anything, they are scumbags and Chinese slaves. I will rather continue to SOPs and wear mask than get in line for vaccine(of course it will change over the time depending on how vaccine is performing among those who took it). But for now, I’m not in any rush whatsoever. I just don’t trust our government

This is what I was saying earlier, because the cure is in line to be a multi-billion dollar windfall, these companies and national govts behind them are now starting to throw dirt on the other in order to get a head start. Too much money at stake to allow someone else to steal in first.

That said, I would still take a vaccine in Britain. I just think the govt would never risk the lawsuits if they passed something which could have health repercussions.
 
Here in Canada lot of folks are opposed to taking vaccine, mostly due to fear of having severe side-effects. It seems govt is pushing general public to blindly trust these ‘so called test results’ and take the vaccine. I personally will wait many weeks if not months to see how it pans out.

Amazing how some conspiracy theorist on YouTube is now more credible to some that actual trained scientists. What would you prefer - a bit of a cold as a side effect to the vaccine, or death or intubation?
 
Amazing how some conspiracy theorist on YouTube is now more credible to some that actual trained scientists. What would you prefer - a bit of a cold as a side effect to the vaccine, or death or intubation?

I survived these many months without vaccine, I’m sure I’ll be just fine. I’m not against vaccine, just that I don’t trust government of Canada as it has been hiding many things from citizens. They are last people on earth I would trust.
Coming to vaccine I will wait few weeks and see how it works. You will be surprised to see how many people here in Canada are opposed to (force) vaccinations. These so called scientists and all are just media hogwash, it’s all about MONEY!
Just went Trump lost election, we see bunch of companies claiming their vaccine works, yea right.
 
I think its sensible to wait to take vaccine. There is nothing wrong with waiting, You want to make sure it doesnt have any unexplained or hitherto unexpected consequences. Doesnt make you a bad person.

I do plan to take it once I am comfortable.
 
After 4.2 million COVID-19 cases in November, U.S. pins hope on vaccine

WASHINGTON (Reuters) - The United States entered the final month of the year hoping that promising vaccine candidates will soon be approved to halt the rapidly spreading novel coronavirus after 4.2 million new cases were reported in November.

The new COVID-19 cases were more than double the previous monthly record set in October, as large numbers of Americans still refuse to refuse to wear masks and continue to gather in holiday crowds, against the recommendation of experts.

With outgoing President Donald Trump’s coronavirus strategy relying heavily on a vaccine, the U.S. Food and Drug Administration is expected to rule on Dec. 10 on whether to approve the emergency use of a vaccine developed by Pfizer Inc.

A second candidate from Moderna Inc could follow a week later, officials have said, raising hopes that Americans could start receiving inoculations before the end the year, although widespread vaccinations could take months.

Other global pharmaceuticals including AstraZeneca PLC and Johnson & Johnson also have vaccines in the works, leading a member of the Trump administration’s “Operation Warp Speed” program to predict the country could be vaccinated by June.

“One hundred percent of the Americans that want the vaccine will have the vaccine by (June). We will have over 300 million doses available to the American public well before then,” Paul Ostrowski, the vaccine program’s director of supply, production and distribution, told MSNBC television on Monday.

In the meantime, leading health officials are pleading with Americans to follow their recommendations and help arrest a pandemic that killed more than 36,000 people in November, pushing hospitalizations to a record high of nearly 93,000 on Sunday, according to a Reuters tally.

The widespread impact of the pandemic has led Merriam-Webster to choose “pandemic” as the Word of the Year after it racked up the most online dictionary lookups of any word.

“Sometimes a single word defines an era, and it’s fitting that in this exceptional - and exceptionally difficult - year, a single word came immediately to the fore,” the dictionary publisher said.

With more than 10,000 people dying and 1.1 million contracting the novel coronavirus in the week ended Sunday, Trump has remained focused on overturning the results of the Nov. 3 election won by President-elect Joe Biden, denying Trump a second term.

Biden has pledged to make combating the coronavirus his top priority upon taking office on Jan. 20, saying he will rely on the best scientific evidence.

In the absence of a federal blueprint to curb the spread of the virus, states are issuing new or revamped restrictions on businesses and social life.

California’s governor said he may renew a stay-at-home order in the coming days, warning that ICU admissions are on track to exceed statewide capacity by mid-December unless public health policies and social behavior change.

“The red flags are flying,” Governor Gavin Newsom told reporters in an online briefing. “If these trends continue, we’re going to have to take much more dramatic, arguably drastic, action.”

https://www.reuters.com/article/us-...vember-u-s-pins-hope-on-vaccine-idUSKBN28B4YV
 
Covid Vaccine Campaigns Could Be Targeted By Criminals, Warns Interpol

(MENAFN - Kashmir Observer)

Lyon- Interpol on Wednesday warned authorities worldwide of the threat from organised crime groups during upcoming Covid-19 vaccination campaigns, including fake vaccines and the theft of supplies.

Distribution of three new coronavirus vaccines is set to begin soon and many people will be desperate to protect themselves as quickly as possible, offering ready targets for criminals.

"As governments are preparing to roll out vaccines, criminal organisations are planning to infiltrate or disrupt supply chains," Juergen Stock, head of the global policing agency based in Lyon, France, said in a statement.

"Criminal networks will also be targeting unsuspecting members of the public via fake websites and false cures, which could pose a significant risk to their health, even their lives," he said.

The agency had already in July warned about the proliferation of fake Covid-19 testing kits and other medical products as countries worldwide rushed to secure supplies during the pandemic.

Its cybercrime unit recently investigated some 3,000 websites linked to online pharmacies selling illicit drugs and other medical products, of which 1,700 also used phishing techniques to try to trick people into handing over personal data, or other malicious software.

"It is important to be vigilant, be skeptical and be safe, as offers which appear too good to be true usually are," the agency said.

Source: https://menafn.com/1101224095/Covid...argeted-By-Criminals-Warns-Interpol&source=22.
 
Vaccine plans announced across Europe

In Spain, Prime Minister Pedro Sanchez said the government intends to vaccinate between 15 million and 20 million people by May or June next year - under half the country's population.

Norway has said it plans to vaccinate nearly a quarter of its population by Easter next year. In the first three months of 2021, pending approval from EU regulators, it expects to receive 2.5 million doses of jabs developed by Moderna, AstraZeneca, Pfizer and BioNTech.

Meanwhile in neighbouring Sweden, the government said it would prioritise vaccines for around 600,000 nursing home residents, as well as their staff and relatives. The Scandinavian nation will receive five variants of the vaccine through the EU's procurement system - the first, by Pfizer and BioNTech, could be approved this month.

Bulgaria has taken a different approach, saying it will prioritise vaccines for doctors, nurses, dentists and pharmacists. The government said it intends to make all inoculations free of charge once they are acquired.
 
Covid: Trials to test combination of Oxford and Sputnik vaccines

UK and Russian scientists are teaming up to trial a combination of the Oxford-AstraZeneca and Sputnik V vaccines to see if protection against Covid-19 can be improved.

Mixing two similar vaccines could lead to a better immune response in people.

The trials, to be held in Russia, will involve over-18s, although it's not clear how many people will be involved.

Oxford recently published results showing their jab was safe and effective in trials on people.

The researchers are still collecting data on the effectiveness of the vaccine in older age groups while waiting for approval from the UK regulator, the MHRA.

AstraZeneca said it was exploring combinations of different adenovirus vaccines to find out whether mixing them leads to a better immune response and, therefore, greater protection.

https://www.bbc.com/news/health-55273907
 
Covid vaccine: US drugs agency FDA to proceed with Pfizer approval

The US Food and Drugs Administration (FDA) has come under renewed White House pressure to approve emergency use of the Pfizer-BioNTech Covid vaccine.

FDA head Stephen Hahn was told to approve it on Friday or quit, US media said, although he called this "untrue".

The spotlight fell on the FDA after its experts on Thursday supported the vaccine. The US health secretary said it should roll out in a couple of days.

The Pfizer vaccine has approval in the UK, Canada, Bahrain and Saudi Arabia.

On Wednesday, the US recorded more than 3,000 deaths - the highest total in a single day anywhere in the world.

What has the FDA said?
On Thursday, medical experts advising the FDA recommended the emergency-use approval. A 23-member panel concluded the vaccine's benefits outweighed its risks.

"Following yesterday's positive advisory committee meeting outcome regarding the Pfizer-BioNTech Covid-19 vaccine, the US Food and Drug Administration has informed the sponsor that it will rapidly work toward finalisation and issuance of an emergency use authorisation," the FDA statement said.

"The agency has also notified the US Centers for Disease Control and Prevention and Operation Warp Speed [the federal government's vaccine distribution programme], so they can execute their plans for timely vaccine distribution."

Has the FDA been leaned on?
On Friday, President Donald Trump sent out an angry tweet calling the FDA a "big, old, slow turtle", adding: "Get the dam vaccines out NOW, Dr Hahn. Stop playing games and start saving lives."

The Washington Post said that White House chief of staff Mark Meadows had ordered FDA Commissioner Hahn to approve the vaccine on Friday or submit his resignation, citing three sources.

But Mr Hahn told US media he had only been "encouraged to continue working expeditiously" on the vaccine's approval, and that the media representation of the chief of staff's phone call was "untrue".

Amid the reports of White House pressure, President-elect Joe Biden said he wanted to make it clear to the public that they should have confidence in the vaccine, adding: "There is no political influence."

What could happen when it is approved?
Operation Warp Speed says that vaccine deliveries will begin within 24 hours of approval.

Mr Azar said the US would work with Pfizer to get the vaccine shipped out so that it could be administered to the most vulnerable people by Monday or Tuesday.

Pfizer plans to have 6.4 million doses ready for the US in its first rollout round in late December.

Because two shots are required per person, that is enough for three million people, out of a total US population of 330 million.

Federal officials at the Centers for Disease Control and Prevention (CDC) say the nation's 21 million healthcare workers should be prioritised first, as well the three million elderly Americans living in long-term care homes.

But there is less consensus on how states should distribute it to other groups. The nation's approximately 87 million essential workers are expected to be next in line for the jab, but it will be up to states to decide which industries to prioritise.

Officials say vaccinations for groups that are not at a high risk are expected to take place in the spring of 2021.

A second vaccine, developed by Moderna and the National Institutes of Health, is also seeking emergency approval in the US. Like the Pfizer vaccine it requires a second round of injections.

Source: https://www.bbc.com/news/world-us-canada-55265477.
 
Covid: Trials to test combination of Oxford and Sputnik vaccines

UK and Russian scientists are teaming up to trial a combination of the Oxford-AstraZeneca and Sputnik V vaccines to see if protection against Covid-19 can be improved.

Mixing two similar vaccines could lead to a better immune response in people.

The trials, to be held in Russia, will involve over-18s, although it's not clear how many people will be involved.

Oxford recently published results showing their jab was safe and effective in trials on people.

The researchers are still collecting data on the effectiveness of the vaccine in older age groups while waiting for approval from the UK regulator, the MHRA.

AstraZeneca said it was exploring combinations of different adenovirus vaccines to find out whether mixing them leads to a better immune response and, therefore, greater protection.

https://www.bbc.com/news/health-55273907

I hope the trial will be in Russia only, I have friends in UK. I trust AstraZeneca but not so much on Russian made stuff.
 
Covid: FDA approves Pfizer vaccine for emergency use in US

The US Food and Drug Administration has authorised the Pfizer-BioNTech coronavirus vaccine for emergency use.

The agency said the authorisation was a "significant milestone" in the pandemic, which taken more than 295,000 lives in the US.

The vaccine, which offers up to 95% protection against Covid-19, was deemed safe and effective by the FDA.

President Donald Trump said the first vaccinations will take place "in less than 24 hours".

"Today our nation has achieved a medical miracle," Mr Trump said. "We have delivered a safe and effective vaccine in just nine months."

Before the announcement on Friday night, the FDA had come under intense pressure from the Trump administration to approve the vaccine's use.

The head of the agency, Stephen Hahn, was told to approve it for emergency use by Friday or quit, US media reported, although he called this "untrue".

Health and Human Services Secretary, Alex Azar, told reporters earlier on Friday that his department would work with Pfizer to get the mass vaccination programme started by Monday or Tuesday.

The Pfizer vaccine has already received regulatory approval in the UK, Canada, Bahrain and Saudi Arabia. Like those countries, the US will give its first doses of the vaccine to the elderly, health workers and emergency crew.

Coronavirus deaths have been rising sharply since November in the US. On Wednesday, the country recorded more than 3,000 deaths - the highest total in a single day anywhere in the world.

https://www.bbc.com/news/world-us-canada-55265477
 
I had the flu jab today. Uptake looked excellent, cars queuing to get into the car park.
 
Covid: First round of US vaccinations to begin on Monday

The US public will start receiving the Pfizer/BioNTech coronavirus vaccine from Monday after it was authorised for emergency use, officials say.

The first three million doses of the vaccine would be shipped "across all states" this weekend, said Gen Gustave Perna, who is overseeing distribution.

The vaccine offers up to 95% protection against Covid-19 and was deemed safe by the Food and Drug Administration (FDA).

On Saturday, the US recorded a daily toll of 3,309 Covid-related deaths.

The figure, reported on the Johns Hopkins University website, is the highest total in a single day anywhere in the world.

Coronavirus deaths have been rising sharply since November in the US.

Authorising the emergency use of the Pfizer/BioNTech vaccine on Friday, the FDA - which had come under intense pressure from the Trump administration to do so - said the move was a "significant milestone" in the pandemic.

A mass inoculation drive using doses of the same vaccine has already begun in the UK.

During a news conference on Saturday, Gen Perna - speaking for the US government's vaccination campaign Operation Warp Speed - said doses of the vaccine would be packed into shipping containers for transportation "within the next 24 hours".

"Expect 145 sites across the states to receive the vaccine on Monday, another 425 sites on Tuesday, and the final 66 sites on Wednesday," he said, adding that next week's distribution would complete the initial delivery of the Pfizer/BioNTech vaccine and cover about three million people.

Gen Perna told reporters he was "100% confident" that the doses "needed to defeat the enemy Covid" would be transported safely.

He warned, however, that while it had been a week of progress, "we are not done until every American has access to a vaccine".

The Pfizer vaccine has already received regulatory approval in the UK, Canada, Bahrain and Saudi Arabia. Like those countries, US health authorities are expected to prioritise health workers and care home residents for the first doses.

More Americans outside the highest-priority groups are likely to be able to get the vaccine in January, with general availability expected by April.

What has the FDA said about the vaccine?
"The FDA's authorisation for emergency use of the first Covid-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world," the head of the agency, Stephen Hahn, said.

He said the authorisation came after "an open and transparent review process" that ensured the vaccine met the "FDA's rigorous, scientific standards for safety, effectiveness, and manufacturing quality".

On Thursday, medical experts advising the FDA recommended the emergency-use authorisation. A 23-member panel concluded the vaccine's benefits outweighed its risks.

Emergency use, the FDA said, was not the same as full approval, which would require Pfizer to file a separate application to secure.

US media reported that Mr Hahn had earlier been told to approve the vaccine for emergency use by Friday or quit.

Mr Hahn, however, said the reports were "untrue" and stressed that the agency had not compromised safety in its testing.

How does the vaccine work?
The Pfizer/BioNTech vaccine was the first coronavirus jab to show promising results in the latter stages of its testing process.

It is a new type called an mRNA vaccine that uses a tiny fragment of genetic code from the pandemic virus to teach the body how to fight Covid-19 and build immunity.

"The vaccine contains a small piece of the [Covid-19] virus's mRNA that instructs cells in the body to make the virus's distinctive 'spike' protein," the FDA said.

"When a person receives this vaccine, their body produces copies of the spike protein, which does not cause disease, but triggers the immune system to learn to react defensively, producing an immune response against [Covid-19]."

The vaccine is given as two injections, 21 days apart, with the second dose being a booster. Immunity begins to kick in after the first dose but reaches its full effect seven days after the second dose.

The vaccine must be stored at ultra-low temperatures, which makes distribution difficult. Special shipping containers that use dry ice will be used to transport frozen vials direct to the point of vaccination, Pfizer says.

The pharmaceutical company has agreed a deal to supply the US with 100 million doses of the vaccine by March.

An additional 200 million doses of a second vaccine, developed by Moderna and the National Institutes of Health, will be provided by June. However this vaccine is still seeking approval in the US.

Source: https://www.bbc.com/news/world-us-canada-55289726.
 
DUBAI, United Arab Emirates (AP) — Bahrain said Sunday it approved the use of a Chinese coronavirus vaccine, following its earlier approval of a vaccine made by Pfizer and its German partner BioNTech.

Separately, Kuwait has granted emergency use for the Pfizer vaccine.

Bahrain’s state-run news agency said the Sinopharm vaccine would be available in the island kingdom off the coast of Saudi Arabia in the Persian Gulf.

It offered few details though on study results of the vaccine, in line with the United Arab Emirates, which last week announced the vaccine was 86% effective. The Emirati statement provided few details but marked the first public release of information on the efficacy of the shot.

Bahrain said over 7,700 signed up to take part in a trial of the Sinopharm vaccine in the kingdom. The kingdom earlier said it plans to give the public free coronavirus vaccines, but has yet to answer any questions about its program.

The Sinopharm vaccine has been approved for emergency use in a few countries and the company is still conducting late-stage clinical trials in 10 countries. Morocco is gearing up for an ambitious COVID-19 vaccination program, aiming to vaccinate 80% of its adults in an operation starting this month that’s relying initially on the Sinopharm vaccine.

Sinopharm’s shot relies on a tested technology, using a killed virus to deliver the vaccine, similar to how polio immunizations are made. Leading Western competitors, like the shot made by Pfizer and its German partner BioNTech, use newer, less-proven technology to target the coronavirus’ spike protein using RNA. The United Kingdom already has begun vaccinating people with the Pfizer shot and the U.S. appears poised to shortly follow.

Already, Pfizer reports its shot as being 95% effective, while another RNA candidate from Moderna appears to be 94.5% effective. Results suggest a third vaccine from Oxford University and AstraZeneca is safe and about 70% effective, but questions remain about how well it may help protect those over 55.

On Sunday, Kuwait’s state-run KUNA news agency announced the oil-rich country’s Health Ministry had granted emergency use for the Pfizer vaccine. Already, the ministry had offered citizens the option to pre-register to receive the vaccine on its website.
 
The United States moved one step closer to getting back to normal this week with the first Covid vaccinations of health care workers around the country. While the majority of Americans won’t get their shots until spring, the vaccine rollout is a hopeful sign of better days ahead. We asked Dr. Anthony S. Fauci, as well as several epidemiologists and health and science writers for The Times, for their predictions about the months ahead. Here’s what they had to say.

What advice do you have for families eager to celebrate the holidays with their loved ones?
“Do it by Zoom. Don’t let Junior come home and kill Grandma. Think of this like World War II — our soldiers didn’t get to fly home to eat turkey. My father was at Normandy. My mother was with the Red Cross in occupied Austria. They missed the holidays. Life went on. There were happier years later.” — Donald G. McNeil Jr., health and science reporter

Will we shake hands again?

“I’m not. I don’t know about you. I said that many, many months ago and the newspapers went wild with it. I’m sure people will get back to shaking hands. I think people will probably become more aware of personal hygiene and protecting yourself. That doesn’t mean nobody will shake hands again, nor does it mean everybody will go back to the way we did it again. Probably somewhere in between. Some people will be reluctant to shake hands. Some people will be washing hands a whole lot more than they ever did, even when Covid-19 is no longer around.” — Dr. Anthony S. Fauci

When would you personally feel comfortable returning to the office?
“When I’m vaccinated and everyone around me is.” — McNeil

Is my employer going to require me to to be vaccinated?
“Employers do have the right to compel their workers to be vaccinated once a vaccine is formally approved. Many hospital systems, for example, require annual flu shots. But employees can seek exemptions based on medical reasons or religious beliefs. In such cases, employers are supposed to provide a ‘reasonable accommodation’; with a coronavirus vaccine, a worker might be allowed to wear a mask in the office instead, or to work from home.” — Abby Goodnough, national health care correspondent

ADVERTISEMENT

Continue reading the main story

Will we ever go to a big, crowded, indoor party without a mask again?
“If the level of infection in the community seems substantial, you’re not going to have the parties with friends in congregant settings. If the level of infection is so low that risk is minuscule, you’re going to see back to the normal congregating together, having parties, doing that. If we want to get back to normal it gets back to my message: When the vaccine becomes available, get vaccinated.” — Dr. Fauci

Do we have to wait for 75 percent of the population to be vaccinated before we can travel again?
“I think traveling is going to start easing up as you get much less than that. I think it’s going to be gradual. There is no black and white, light switch on, light switch off.” — Dr. Fauci

Unlock more free articles.
Create an account or log in
How long will we be wearing masks?
“If you get herd immunity where there are no infections around, you wouldn’t have to wear a mask all the time. You might want to wear it if you were in a crowded situation, but you wouldn’t have to have the stringency you have now. Ultimately, I think you’re going to have to transition from wearing all the time, to wearing it under certain circumstances, to perhaps not having to wear it at all.” — Dr. Fauci

OPINION TODAY: Get expert analysis of the news and a guide to the big ideas shaping the world.
Sign Up
How will we know it’s safe to do normal things?
“First of all, it’s going to be expressed by the number of new cases that you see — the test positivity number. You’ve got to go as low as you can get. The best number is zero. It’s never going to be zero, but anywhere close to that is great.” — Dr. Fauci

When can we go to the movies or the theater?
“It depends on the uptake of the vaccine and the level of infection in the community. If you go to April, May, June and you really put on a full-court press and try to vaccinate everybody within a period of a few months, as you go from second to third quarter of the year, then you could likely go to movies, go to theaters, do what you want. However, it’s unlikely, given what we’re hearing about people’s desire to get vaccinated, that we’re going to have that degree of uptake. If it turns out that only 50 percent get vaccinated, then it’s going to take much, much longer to get back to the kind of normality that we’d like to see.” — Dr. Fauci

Editors’ Picks

‘It Was My First Day Going to Work After Moving Into a House in Midwood’

Holidays in a Pandemic? Here’s What Happened in 1918

What’s Fauci Reading? We Take Another Look at Celebrity Bookshelves
ADVERTISEMENT

Continue reading the main story

When will you eat in a restaurant?
“If more than half the population is vaccinated, I would feel a little less stressed and anxious when heading out to do errands I normally do. I might actually feel comfortable to eat in a restaurant or see friends again one day if this is possible.”— Vijaya L. Seegulam, research project manager, Boston University

Covid-19 Vaccines ›
Answers to Your Vaccine Questions
With distribution of a coronavirus vaccine beginning in the U.S., here are answers to some questions you may be wondering about:

If I live in the U.S., when can I get the vaccine? While the exact order of vaccine recipients may vary by state, most will likely put medical workers and residents of long-term care facilities first. If you want to understand how this decision is getting made, this article will help.
When can I return to normal life after being vaccinated? Life will return to normal only when society as a whole gains enough protection against the coronavirus. Once countries authorize a vaccine, they’ll only be able to vaccinate a few percent of their citizens at most in the first couple months. The unvaccinated majority will still remain vulnerable to getting infected. A growing number of coronavirus vaccines are showing robust protection against becoming sick. But it’s also possible for people to spread the virus without even knowing they’re infected because they experience only mild symptoms or none at all. Scientists don’t yet know if the vaccines also block the transmission of the coronavirus. So for the time being, even vaccinated people will need to wear masks, avoid indoor crowds, and so on. Once enough people get vaccinated, it will become very difficult for the coronavirus to find vulnerable people to infect. Depending on how quickly we as a society achieve that goal, life might start approaching something like normal by the fall 2021.
If I’ve been vaccinated, do I still need to wear a mask? Yes, but not forever. Here’s why. The coronavirus vaccines are injected deep into the muscles and stimulate the immune system to produce antibodies. This appears to be enough protection to keep the vaccinated person from getting ill. But what’s not clear is whether it’s possible for the virus to bloom in the nose — and be sneezed or breathed out to infect others — even as antibodies elsewhere in the body have mobilized to prevent the vaccinated person from getting sick. The vaccine clinical trials were designed to determine whether vaccinated people are protected from illness — not to find out whether they could still spread the coronavirus. Based on studies of flu vaccine and even patients infected with Covid-19, researchers have reason to be hopeful that vaccinated people won’t spread the virus, but more research is needed. In the meantime, everyone — even vaccinated people — will need to think of themselves as possible silent spreaders and keep wearing a mask. Read more here.
Will it hurt? What are the side effects? The Pfizer and BioNTech vaccine is delivered as a shot in the arm, like other typical vaccines. The injection into your arm won’t feel different than any other vaccine, but the rate of short-lived side effects does appear higher than a flu shot. Tens of thousands of people have already received the vaccines, and none of them have reported any serious health problems. The side effects, which can resemble the symptoms of Covid-19, last about a day and appear more likely after the second dose. Early reports from vaccine trials suggest some people might need to take a day off from work because they feel lousy after receiving the second dose. In the Pfizer study, about half developed fatigue. Other side effects occurred in at least 25 to 33 percent of patients, sometimes more, including headaches, chills and muscle pain. While these experiences aren’t pleasant, they are a good sign that your own immune system is mounting a potent response to the vaccine that will provide long-lasting immunity.
Will mRNA vaccines change my genes? No. The vaccines from Moderna and Pfizer use a genetic molecule to prime the immune system. That molecule, known as mRNA, is eventually destroyed by the body. The mRNA is packaged in an oily bubble that can fuse to a cell, allowing the molecule to slip in. The cell uses the mRNA to make proteins from the coronavirus, which can stimulate the immune system. At any moment, each of our cells may contain hundreds of thousands of mRNA molecules, which they produce in order to make proteins of their own. Once those proteins are made, our cells then shred the mRNA with special enzymes. The mRNA molecules our cells make can only survive a matter of minutes. The mRNA in vaccines is engineered to withstand the cell's enzymes a bit longer, so that the cells can make extra virus proteins and prompt a stronger immune response. But the mRNA can only last for a few days at most before they are destroyed.

When will you feel comfortable in a crowd?
“Once my family and I are vaccinated, I would change behaviors, except I can’t imagine being in a crowd or attending any crowded events until at least 80 percent of the population is vaccinated.”— Julie Bettinger, associate professor, University of British Columbia

When will restrictions start to ease up?
“I think widespread availability of vaccines will result in the further relaxation of most precautions by mid- to late summer 2021.” — Michael Webster-Clark, postdoctoral researcher, University of North Carolina at Chapel Hill

What will the new normal look like?
“The new normal will be continued masking for the next 12 to 18 months and possibly the next few years. This is a paradigm shift.” — Roberta Bruhn, epidemiology core co-director, Vitalant Research Institute

What will never return to normal?
“My relationships with people who have taken this pandemic lightly and ignored public health messages and recommendations.” — Victoria Holt, professor emeritus, University of Washington

What did you learn from pandemic life?
“Staying home with my children has taught me that life with fewer errands to run and activities to partake in is kind of nice. I think in the future we will cut down on our family obligations.” — Jennifer Nuzzo, associate professor, Johns Hopkins

What pandemic habit will you keep?
“I’m going to keep my mask, and wear it in crowds and on subways, particularly during cold and flu season. I used to get sick all the time, but I haven’t had a cold or sore throat in months. I really like not getting sick!”

What’s one thing you’ll never take for granted again?
“I won’t take traveling to my extended family for granted.” — Alicia Allen, assistant professor, University of Arizona

What has forever changed in your daily life?
“I will never again have to explain what an epidemiologist is.” — Janet Rich-Edwards, associate professor, Harvard


https://www.nytimes.com/2020/12/16/well/live/life-after-covid.html?referringSource=articleShare
 
'The beginning of the end': Europe rolls out vaccines to fight pandemic

MADRID/ROME (Reuters) - Europe launched a mass COVID-19 vaccination drive on Sunday with pensioners and medics lining up to get the first shots to see off a pandemic that has crippled economies and claimed more than 1.7 million lives worldwide.

“Thank God,” 96-year-old Araceli Hidalgo said as she became the first person in Spain to have a vaccine at her care home in Guadalajara near the capital Madrid. “Let’s see if we can make this virus go away.”

In Italy, the first country in Europe to record significant numbers of infections, 29-year-old nurse Claudia Alivernini was one of three medical staff at the head of the queue for the shot developed by Pfizer and BioNTech.

“It is the beginning of the end ... it was an exciting, historic moment,” she said at Rome’s Spallanzani hospital.

The region of 450 million people is trying to catch up with the United States and Britain which have both already started vaccinations using the Pfizer/BioNTech shot.

The EU is due to receive 12.5 million doses of the shot by the end of the year, enough to vaccinate 6.25 million people based on the two-dose regimen. The companies are scrambling to meet global demand and aim to make 1.3 billion shots next year.

Europe has secured contracts with a range of drugmakers besides Pfizer including Moderna and AstraZeneca, for a total of more than two billion vaccine doses and has set a goal for all adults to be inoculated during 2021.

While Europe has some of the best-resourced healthcare systems in the world, the sheer scale of the effort means some countries are calling on retired medics to help while others have loosened rules for who is allowed to give the injections.

With surveys pointing to high levels of hesitancy towards the vaccine in countries from France to Poland, leaders of the 27-country European Union are promoting it as the best chance of getting back to something like normal life next year.

“We have a new weapon against the virus: the vaccine. We must stand firm, once more,” tweeted French President Emmanuel Macron, who tested positive for the coronavirus this month and left quarantine on Christmas Eve.

https://www.reuters.com/article/hea...-out-vaccines-to-fight-pandemic-idUSKBN2910BQ
 
Covid vaccines: Macron proposes sending 4-5% of doses to poorer nations

French President Emmanuel Macron has called on Europe and the US to urgently send up to 5% of their coronavirus vaccine supplies to developing nations.

Mr Macron told the Financial Times the failure to share vaccines fairly would entrench global inequality.

The vast majority of vaccinations have been administered by high-income countries so far.

Mr Macron proposed his plan to address the imbalance ahead of a G7 virtual summit of world leaders on Friday.

The White House has said US President Joe Biden will announce a pledge of $4bn (£2.8bn) in funding for Covax at the meeting.

UK Prime Minister Boris Johnson - who will chair the meeting - is expected to dedicate surplus doses to a global vaccine-sharing scheme, known as Covax.

To date, at least 110 million people have been infected with the virus worldwide and more than 2.4 million have died, according to figures from Johns Hopkins University.

Source: https://www.bbc.com/news/world-europe-56121062.
 
Johnson and Johnson vaccine: FDA finds the single-shot jab safe

A review by US regulators of the single-shot Johnson & Johnson coronavirus vaccine has found it is safe and effective.

It paves the way for it to become the third Covid-19 vaccine to be authorised in the US, possibly within days.

The vaccine would be a cost-effective alternative to the Pfizer and Moderna vaccines, and can be stored in a refrigerator instead of a freezer.

Results from trials were released by Johnson & Johnson last month.

The Belgian company Janssen, which is owned by the pharmaceutical giant, said its data showed the product was highly effective against severe disease.

It comes as Ghana became the first country to receive coronavirus vaccines through the Covax vaccine-sharing initiative.

The briefing document published by the US Food and Drug Administration (FDA) gives more detail on the data submitted by Janssen to the regulator. The FDA concludes that the Johnson & Johnson vaccine has "known benefits" in reducing both symptomatic and severe illness.

Results from vaccine trials conducted in the US, South Africa and Brazil found its efficacy against the worst outcomes of the virus was "similarly high" but overall protection was lower in South Africa and Brazil, where virus variants have become dominant.

Data showed it was more than 85% effective at preventing serious illness, but only 66% effective overall, when moderate cases were included, when considering cases at least 28 days after vaccination.

Notably, there were no deaths among participants who had received the vaccine and no hospital admissions after 28 days post-vaccine.

An external committee of experts will meet on Friday to recommend whether the FDA should authorise the vaccine, possibly adding to a coming surge in vaccine availability in the US.

A White House official said the administration anticipated distributing at least three million doses of the Johnson & Johnson vaccine next week, should it receive emergency authorisation from the FDA.

The company says it plans to deliver 20 million doses in total by late March, in line with an agreement to supply the US with 100m doses by the end of June.

Source: https://www.bbc.com/news/world-us-canada-56186965.
 
Covax vaccine-sharing scheme delivers first doses to Ghana

Ghana has become the first country to receive coronavirus vaccines through the Covax vaccine-sharing initiative.

A delivery of 600,000 doses of the AstraZeneca vaccine arrived in Accra on Wednesday. The first recipients are due to be healthcare workers.

The Covax scheme aims to reduce the divide between rich countries and poorer nations unable to buy doses.

The programme is planning to deliver about two billion vaccine doses globally by the end of the year.

Ghana, which has a population of over 30m, was chosen as the first recipient of the free vaccines after promising quick distribution and meeting the criteria set by Covax.

Further deliveries are expected to neighbouring Ivory Coast later this week, the Covax alliance says.

Vaccinations are expected to start in Ghana next week, and, as well as health workers, those over 60, people with underlying health conditions, and senior officials are due to be prioritised.

The vaccines delivered to Accra were produced by the Serum Institute of India and developed by AstraZeneca and Oxford University. The vaccine has been approved by the World Health Organization (WHO) and its roll-out in Ghana is not part of a trial.

The doses being sent to lower-income countries such as Ghana are funded by donations. As well as procuring and delivering the vaccines, Covax partners are supporting local authorities in areas such as training people to administer the jabs and helping provide an adequate cold-chain storage and delivery system.

Many nations in the developed world, which began their own vaccinations months ago, have faced criticism for buying or ordering more vaccines than they need.

But many of those countries placed orders for doses with pharmaceutical companies before knowing whether the vaccine in development would be effective. They were hedging their bets - placing multiple orders in the hope that at least some of them would work out.

The UK, which has ordered 400 million vaccine doses and will have many left over, has said it will donate most of its surplus vaccine supply to poorer countries.

The Covax scheme is led by the WHO and also involves the Global Vaccine Alliance (Gavi) and the Coalition for Epidemic Preparedness Innovations (Cepi).

In a joint statement, the WHO and the United Nations children's fund (Unicef) said it was a momentous occasion and "critical in bringing the pandemic to an end".

Ghana has recorded more than 80,700 cases of coronavirus and 580 deaths since the pandemic began. These numbers are believed to fall short of the actual toll because of low levels of testing.

Though the vaccines are not generally intended for children, Unicef is involved in the scheme because of its expertise in procurement and the logistics of vaccine delivery.

Source: https://www.bbc.com/news/world-africa-56180161.
 
Johnson & Johnson Covid vaccine: FDA approves single-shot jab

US regulators have formally approved the single-shot Johnson & Johnson coronavirus vaccine, the third jab to be authorised in the country.

The vaccine is set to be a cost-effective alternative to the Pfizer and Moderna vaccines, and can be stored in a refrigerator instead of a freezer.

Trials found it prevented serious illness but was 66% effective overall when moderate cases were included.

The vaccine is made by the Belgian firm Janssen.

The company has agreed to provide the US with 100 million doses by the end of June. The first doses could be available to the US public as early as next week.

The UK, EU and Canada have also ordered doses, and 500 million doses have also been ordered through the Covax scheme to supply poorer nations.

President Joe Biden hailed it as "exciting news for all Americans, and an encouraging development", but warned that the "fight is far from over".

"Though we celebrate today's news, I urge all Americans - keep washing your hands, stay socially distanced, and keep wearing masks," he said in a statement.

"As I have said many times, things are still likely to get worse again as new variants spread, and the current improvement could reverse."

The authorisation by the US Food and Drug Administration (FDA) came after an external committee of experts unanimously backed the vaccine on Friday.

Results from trials conducted in the US, South Africa and Brazil showed it was more than 85% effective at preventing serious illness, and 66% effective overall when moderate cases were included.

Notably, there were no deaths among participants who had received the vaccine and no hospital admissions after 28 days post-vaccine.

Overall protection was lower in South Africa and Brazil, where virus variants have become dominant, but defence against severe or critical illness was "similarly high".

South Africa began administering the unapproved Johnson & Johnson jab to healthcare workers as part of a study earlier this month. It came after early trials suggested the Oxford-AstraZeneca vaccine offered "minimal protection" against mild disease from the variant dominant in large parts of the country.

So far the only other country to approve the vaccine for emergency use is Bahrain, which gave it the green light on Thursday.

Because the vaccine will require fewer doses than its two-shot Pfizer and Moderna counterparts, it will also require fewer vaccine appointments and medical staff.

Source: https://www.bbc.com/news/world-us-canada-56226979.
 
Back
Top